Accretive Wealth Partners’s ProPhase Labs PRPH Stock Holding History

Accretive Wealth Partners’s Portfolio PRPH Stock Details PRPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$114K	–	160
2025 Q3	$114K	Buy	+25,000	New	+$96.6K	0.03%	151

Other funds holding PRPH

Sykon Capital Harrison, New York $325M AUM 19.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Accretive Wealth Partners's PRPH Position: Q4 2025 in Review

Accretive Wealth Partners sold out of ProPhase Labs (PRPH) in Q4 2025, closing a stake of 25,000 shares — an estimated $114K sold.

Accretive Wealth Partners first reported a position in PRPH in Q3 2025 and held it in 1 quarter. The position peaked at $114K in Q3 2025. 17 funds tracked by Wall St. Rank hold PRPH as of Q4 2025.

Accretive Wealth Partners reported no remaining ProPhase Labs position as of Q4 2025 after selling out during the quarter.
Accretive Wealth Partners sold 25,000 ProPhase Labs shares in Q4 2025, an estimated $114K.
Accretive Wealth Partners first reported a position in ProPhase Labs in Q3 2025 and held it in 1 quarter.
Accretive Wealth Partners's ProPhase Labs position peaked at $114K in Q3 2025.
17 funds tracked by Wall St. Rank held ProPhase Labs as of Q4 2025.

Based on Accretive Wealth Partners's 13F filing for Q4 2025, filed 28 Jan 2026.